New therapeutic agents in diabetic nephropathy

키워드

참고문헌 (79)

1. Jha V, "Chronic kidney disease: global dimension and perspectives", Lancet, 382, pp.260~272 (2013)
2. Foley RN, "Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998to 1999", J Am Soc Nephrol, 16, pp.489~495 (2005)
3. Keith DS, "Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization", Arch Intern Med, 164, pp.659~663 (2004)
4. 김성권, "The Prevalence of Chronic Kidney Disease (CKD) and the Associated Factors to CKD in Urban Korea: A Population-based Cross-sectional Epidemiologic Study", Journal of Korean Medical Science, 24, pp.11~21 (2009), 대한의학회
5. 진동찬, "Major changes and improvements of dialysis therapy in Korea: review of end-stage renal disease registry", The Korean Journal of Internal Medicine, 30(1), pp.17~22 (2015), 대한내과학회[DOI]
6. 박철휘, "Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives", Diabetes and Metabolism Journal, 38(4), pp.252~260 (2014), 대한당뇨병학회[DOI]
7. Ruggenenti P, "Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?", Nephrol Dial Transplant, 15, pp.1900~1902 (2000)
8. Barnes DJ, "Oxford Textbook of Clinical Nephrology", pp.723~775 (1998), Oxford University Press
9. Vallon V, "Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney", Annu Rev Physiol, 74, pp.74~351 (2012)
10. Saad S, "High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule", Kidney Int, 68, pp.985~997 (2005)
11. Nishikawa T, "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage", Nature, 404, pp.787~790 (2000)
12. Navarro-Gonzalez JF, "Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy", Nat Rev Nephrol, 7, pp.327~340 (2011)
13. Fioretto P, "Histopathology of diabetic nephropathy", Semin Nephrol, 27, pp.195~207 (2007)
14. Rutledge JC, "Role of triglyceride-rich lipoproteins in diabetic nephropathy", Nat Rev Nephrol, 6, pp.361~370 (2010)
15. Cooper ME, "Lipids and diabetic renal disease", Curr Diab Rep, 5, pp.445~448 (2005)
16. Bobulescu IA., "Renal lipid metabolism and lipotoxicity", Curr Opin Nephrol Hypertens, 19, pp.393~402 (2010)
17. Jiang T, "Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy", Diabetes, 56, pp.2485~2493 (2007)
18. Herman-Edelstein M, "Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy", J Lipid Res, 55, pp.561~572 (2014)
19. Klag MJ, "Blood pressure and end-stage renal disease in men", N Engl J Med, 334, pp.13~18 (1996)
20. Iseki K, "Proteinuria and the risk of developing end-stage renal disease", Kidney Int, 63, pp.1468~1474 (2003)
21. Locatelli F, "Proteinuria and blood pressure as causal components of progression to end-stage renal failure: Northern Italian Cooperative Study Group", Nephrol Dial Transplant, 11, pp.461~467 (1996)
22. Iseki K, "Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan", Am J Kidney Dis, 44, pp.806~814 (2004)
23. Abbate M, "How does proteinuria cause progressive renal damage?", J Am Soc Nephrol, 17, pp.2974~2984 (2006)
24. Basi S, "Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?", Diabetes Care, 31(Suppl 2), pp.S194~S201 (2008)
25. Perkins BA, "In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria", Kidney Int, 77, pp.57~64 (2010)
26. Gaede P, "Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes", N Engl J Med, 348, pp.383~393 (2003)
27. Brenner BM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", N Engl J Med, 345, pp.861~869 (2001)
28. Lewis EJ, "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", N Engl J Med, 345, pp.851~860 (2001)
29. Azizi M, "Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists", Circulation, 109, pp.2492~2499 (2004)
30. Azizi M, "Renin inhibition with aliskiren: where are we now, and where are we going?", J Hypertens, 24, pp.243~256 (2006)
31. Muller DN, "Direct renin inhibition with aliskiren in hypertension and target organ damage", Clin J Am Soc Nephrol, 1, pp.221~228 (2006)
32. Persson F, "Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy", Diabetes Care, 33, pp.2304~2309 (2010)
33. Navaneethan SD, "Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis", Clin J Am Soc Nephrol, 4, pp.542~551 (2009)
34. Palmer SC, "Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis", Ann Intern Med, 157, pp.263~275 (2012)
35. Rodrigues CJ., "HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis", Sao Paulo Med J, 133, pp.541~542 (2015)
36. Mann JF, "Avosentan for overt diabetic nephropathy", J Am Soc Nephrol, 21, pp.527~535 (2010)
37. Schievink B, "Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers", Eur J Prev Cardiol, 23, pp.758~768 (2016)
38. de Zeeuw D, "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease", N Engl J Med, 369, pp.2492~2503 (2013)
39. Packham DK, "Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy", J Am Soc Nephrol, 23, pp.123~130 (2012)
40. Coyne DW, "Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study", Nephrol Dial Transplant, 28, pp.2260~2268 (2013)
41. Lindhardt M, "Proteomic prediction and renin angiotensin aldosterone system Inhibition prevention of early diabetic nephropathy in type 2 diabetic patients with normoalbuminuria (PRIORITY):essential study design and rationale of a randomised clinical multicentre trial", BMJ Open, 6, pp.e010310~ (2016)
42. Sircar D, "Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial", Am J Kidney Dis, 66, pp.945~950 (2015)
43. Navarro-Gonzalez JF, "Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial", J Am Soc Nephrol, 26, pp.220~229 (2015)
44. Abdel Aziz MT, "The role of bone marrow derived-mesenchymal stem cells in attenuation of kidney function in rats with diabetic nephropathy", Diabetol Metab Syndr, 6, pp.34~ (2014)
45. Ezquer F, "Proregenerative microenvironment triggered by donor mesenchymal stem cells preserves renal function and structure in mice with severe diabetes mellitus", Biomed Res Int, 2015, pp.164703~ (2015)
46. Vilsboll T, "Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients", Diabetes, 50, pp.609~613 (2001)
47. Ahren B, "Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance", Eur J Endocrinol, 137, pp.127~131 (1997)
48. Vilsboll T, "Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients", Diabetologia, 45, pp.1111~1119 (2002)
49. Drucker DJ., "Biological actions and therapeutic potential of the glucagon-like peptides", Gastroenterology, 122, pp.531~544 (2002)
50. Nauck MA, "Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans", Am J Physiol, 273(5 Pt 1), pp.E981~E988 (1997)
51. Verdich C, "A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans", J Clin Endocrinol Metab, 86, pp.4382~4389 (2001)
52. Muskiet MH, "The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?", Nat Rev Nephrol, 10, pp.88~103 (2014)
53. Hattori S., "Sitagliptin reduces albuminuria in patients with type 2 diabetes", Endocr J, 58, pp.69~73 (2011)
54. Sakata K, "Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE):receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes", Diabetes Metab Res Rev, 29, pp.624~630 (2013)
55. Groop PH, "Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction", Diabetes Care, 36, pp.3460~3468 (2013)
56. Zhang H, "Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria", Kidney Blood Press Res, 35, pp.483~488 (2012)
57. Kanasaki K, "Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen", Diabetes, 63, pp.2120~2131 (2014)
58. Wong MG, "Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1", Am J Physiol Renal Physiol, 301, pp.F84~F93 (2011)
59. Panchapakesan U, "DPP-4 inhibitors-renoprotection in diabetic nephropathy?", Diabetes, 63, pp.1829~1830 (2014)
60. Ghosh RK, "SGLT2inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus", J Clin Pharmacol, 52, pp.457~463 (2012)
61. Thomson SC, "Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat", Am J Physiol Regul Integr Comp Physiol, 302, pp.R75~R83 (2012)
62. Panchapakesan U, "Effects of SGLT2inhibition in human kidney proximal tubular cells:renoprotection in diabetic nephropathy?", PLoS One, 8, pp.e54442~ (2013)
63. Cefalu WT, "Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial", Lancet, 382, pp.941~950 (2013)
64. Nicolle LE, "Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2)inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study", Curr Med Res Opin, 28, pp.1167~1171 (2012)
65. Kohan DE, "Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control", Kidney Int, 85, pp.962~971 (2014)
66. Musso G, "A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials", Ann Med, 44, pp.375~393 (2012)
67. Vasilakou D, "Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes:a systematic review and meta-analysis", Ann Intern Med, 159, pp.262~274 (2013)
68. Viollet B, "Targeting the AMPK pathway for the treatment of type 2 diabetes", Front Biosci (Landmark Ed), 14, pp.3380~3400 (2009)
69. Dronavalli S, "The pathogenesis of diabetic nephropathy", Nat Clin Pract Endocrinol Metab, 4, pp.444~452 (2008)
70. Hardie DG, "AMPK: a nutrient and energy sensor that maintains energy homeostasis", Nat Rev Mol Cell Biol, 13, pp.251~262 (2012)
71. Hallows KR, "Role of the energy sensor AMP-activated protein kinase in renal physiology and disease", Am J Physiol Renal Physiol, 298, pp.F1067~F1077 (2010)
72. Kim MY, "Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db", db mice, 2013, pp.56, 204~217
73. Hawley SA, "5’-AMP activates the AMP-activated protein kinase cascade, and Ca2+", calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms, 1995, pp.270, 27186~27191
74. Momcilovic M, "Mammalian TAK1activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro", J Biol Chem, 281, pp.25336~25343 (2006)
75. Hawley SA, "Complexes between the LKB1 tumor suppressor, STRAD alpha", beta and MO25 alpha, J Biol, pp.2003, 2[DOI]
76. Sanders MJ, "Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family", J Biol Chem, 282, pp.32539~32548 (2007)
77. Hong YA, "Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1alpha in db", db mice, 2014, pp.9, e96147~
78. Koh ES, "Anthocyanin-rich Seoritae extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice", J Transl Med, 13, pp.203~ (2015)
79. Yaeni Kim, "Adenosine monophosphateeactivated protein kinase in diabetic nephropathy", Kidney Research and Clinical Practice, 35(2), pp.69~77 (2016), 대한신장학회

관련 논문AI추천